AIMS/HYPOTHESIS: We analysed the association between humoral autoreactivity to zinc transporter-8 (ZnT8) and the SLC30A8 rs13266634 polymorphism (Arg325Trp), which is located at the most distal loop in the ZnT8 protein. METHODS: Autoantibodies to ZnT8 were determined by RIA in 270 patients with type 1 diabetes using ZnT8 carboxy-terminal constructs (amino acids 268-369) carrying 325Trp(CW) and 325Arg(CR) and a hybrid construct (CW-CR). Forty-four ZnT8 autoantibody-positive sera with genomic DNA were used to examine the association between reactivity to ZnT8 constructs and the rs13266634 genotype. RESULTS: Seventy-five patients reacted to the CW-CR hybrid construct, whereas 37 and 36 patients reacted to the CW and CR constructs, respectively. All sera positive for either CW or CR autoantibodies were positive for CW-CR autoantibodies. Among 19 patients with a 325Arg(CC) genotype, 5% had CW-specific autoantibodies, 42% had CR-specific autoantibodies and 32% had dual reactivity. Conversely, 73% of 15 patients with the 325Trp(TT) genotype had CW-specific autoantibodies, no patients had CR-specific autoantibodies and 13% had dual reactivity. Nine of the ten patients (90%) with the CT genotype reacted with either CR or CW constructs. The titre of CR autoantibodies in patients carrying the C allele was significantly higher than that in TT homozygotes (p < 0.0001). In contrast, the titre of CW autoantibodies in patients carrying a T allele was significantly higher than that in CC homozygotes (p < 0.005). No evidence of an association between rs13266634 and type 1 diabetes was observed. CONCLUSIONS/ INTERPRETATION: These results indicate that variant residue at amino acid 325 is a key determinant of humoral autoreactivity to ZnT8 and that the SLC30A8 genotype is an important determinant of autoantibody specificity.
AIMS/HYPOTHESIS: We analysed the association between humoral autoreactivity to zinc transporter-8 (ZnT8) and the SLC30A8rs13266634 polymorphism (Arg325Trp), which is located at the most distal loop in the ZnT8 protein. METHODS: Autoantibodies to ZnT8 were determined by RIA in 270 patients with type 1 diabetes using ZnT8 carboxy-terminal constructs (amino acids 268-369) carrying 325Trp(CW) and 325Arg(CR) and a hybrid construct (CW-CR). Forty-four ZnT8 autoantibody-positive sera with genomic DNA were used to examine the association between reactivity to ZnT8 constructs and the rs13266634 genotype. RESULTS: Seventy-five patients reacted to the CW-CR hybrid construct, whereas 37 and 36 patients reacted to the CW and CR constructs, respectively. All sera positive for either CW or CR autoantibodies were positive for CW-CR autoantibodies. Among 19 patients with a 325Arg(CC) genotype, 5% had CW-specific autoantibodies, 42% had CR-specific autoantibodies and 32% had dual reactivity. Conversely, 73% of 15 patients with the 325Trp(TT) genotype had CW-specific autoantibodies, no patients had CR-specific autoantibodies and 13% had dual reactivity. Nine of the ten patients (90%) with the CT genotype reacted with either CR or CW constructs. The titre of CR autoantibodies in patients carrying the C allele was significantly higher than that in TT homozygotes (p < 0.0001). In contrast, the titre of CW autoantibodies in patients carrying a T allele was significantly higher than that in CC homozygotes (p < 0.005). No evidence of an association between rs13266634 and type 1 diabetes was observed. CONCLUSIONS/ INTERPRETATION: These results indicate that variant residue at amino acid 325 is a key determinant of humoral autoreactivity to ZnT8 and that the SLC30A8 genotype is an important determinant of autoantibody specificity.
Authors: Robert Sladek; Ghislain Rocheleau; Johan Rung; Christian Dina; Lishuang Shen; David Serre; Philippe Boutin; Daniel Vincent; Alexandre Belisle; Samy Hadjadj; Beverley Balkau; Barbara Heude; Guillaume Charpentier; Thomas J Hudson; Alexandre Montpetit; Alexey V Pshezhetsky; Marc Prentki; Barry I Posner; David J Balding; David Meyre; Constantin Polychronakos; Philippe Froguel Journal: Nature Date: 2007-02-11 Impact factor: 49.962
Authors: E Kawasaki; Y Sera; N Fujita; M Yamauchi; M Ozaki; T Abe; K Yamakawa; S Uotani; H Takino; H Yamasaki; Y Yamaguchi; Y Uchigata; N Matsuura; K Eguchi Journal: J Autoimmun Date: 2001-12 Impact factor: 7.094
Authors: Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205
Authors: Janet M Wenzlau; Yu Liu; Liping Yu; Ong Moua; Kimberly T Fowler; Sampathkumar Rangasamy; Jay Walters; George S Eisenbarth; Howard W Davidson; John C Hutton Journal: Diabetes Date: 2008-06-30 Impact factor: 9.461
Authors: J M Wenzlau; M Walter; T J Gardner; L M Frisch; L Yu; G S Eisenbarth; A-G Ziegler; H W Davidson; J C Hutton Journal: J Clin Endocrinol Metab Date: 2010-07-07 Impact factor: 5.958
Authors: Lin Yang; Shuoming Luo; Gan Huang; Jian Peng; Xia Li; Xiang Yan; Jian Lin; Janet M Wenzlau; Howard W Davidson; John C Hutton; Zhiguang Zhou Journal: Diabetes Metab Res Rev Date: 2010-10 Impact factor: 4.876
Authors: Peter Arvan; Massimo Pietropaolo; David Ostrov; Christopher J Rhodes Journal: Cold Spring Harb Perspect Med Date: 2012-08-01 Impact factor: 6.915
Authors: Oindrila Raha; Subhankar Chowdhury; Samir Dasgupta; P Raychaudhuri; B N Sarkar; P Veer Raju; V R Rao Journal: Int J Diabetes Dev Ctries Date: 2009-04
Authors: J De Grijse; M Asanghanwa; B Nouthe; N Albrecher; P Goubert; I Vermeulen; S Van Der Meeren; K Decochez; I Weets; B Keymeulen; V Lampasona; J Wenzlau; J C Hutton; D Pipeleers; F K Gorus Journal: Diabetologia Date: 2009-11-29 Impact factor: 10.122
Authors: Janet M Wenzlau; Lisa M Frisch; Thomas J Gardner; Suparna Sarkar; John C Hutton; Howard W Davidson Journal: Curr Diab Rep Date: 2009-04 Impact factor: 4.810